With promising efficacy in mouse models of melanoma and lymphoma, the combination of anti-B7-H3 and anti-PD-1 antibody therapies is regarded as a promising strategy for PD-1 inhibitor-resistant NSCLC, with promising synergistic effects for PDAC [53]. This evidence concerns the gene CD276 and melanoma.